



Northern Health October Formulary Update

New Formulary Medications:

- a. dorzolamide-timolol (COSOPT®) combination ophthalmic drops
- b. etomidate (TOMVI®) injection
- c. latanoprost-timolol (XALACOM®) combination ophthalmic drops
- d. sodium phosphate effervescent tablet

New Formulary Restricted Medications:

- a. methoxsalen (UVADEX®) injection: restricted to indications outlined in the BC Cancer Benefit Drug List AND patients who are registered with BC Cancer
- b. Centre for Excellence (CFE) addition of following medications restricted to approval by the CFE in HIV/AIDS:
 - doravirine (PIFELTRO®) oral tablet
 - doravirine-lamivudine-tenofovir DF (DELSTRIGO®) oral tablet

Updates to Formulary Therapeutic Interchange Program (TIP):

- a. latanoprost-timolol (XALACOM®) combination ophthalmic drops: travoprost 0.004%-timolol 0.5% (DUOTRAV®) combination ophthalmic drops will be changed to latanoprost 0.005%-timolol 0.5% at same number of drops and frequency. See NHA TIP list for details.

Enoxaparin Biosimilar Strategy:

- a. All Health Canada biosimilar enoxaparin products (REDESCA®, NOROMBY™, INCLUNOX®) will be considered highly similar and therapeutically equivalent to the reference biologic (LOVENOX®) as determined by the BC Pharmacy & Therapeutics Committee.

Discontinued Medications:

- a. paraldehyde injection
- b. saquinavir (INVIRASE®) oral tablet and capsule

October 5, 2021 For the information of physicians, nurses, and pharmacists. PLEASE POST	Formulary Changes	√	For further information contact: <i>Jessica Granberg *or* Ryan Doerksen</i> Medication Use Management Pharmacists mumpharmacist@northernhealth.ca
	Drug Discontinuation		
	Medication Change		